Pulmonary macrophages may contribute to the relative insensitivity to cortocosteroids in chronic lung diseases]. Dexamethasone has been shown to improve efferocytosis while in patients with severe asthma, defective efferocytosis was improved after a course of high dose steroids. In COPD, lung macrophages have reduced expression of the epigenetic modifying enzyme histone deacetylase 2 (HDAC2) and this is associated with increased expression of inflammatory genes and also resistance to corticosteroids.
Statins also have been shown to improve macrophage phagocytic function mediated in part by their inhibitory effects on RhoA. In COPD, there is evidence of an improved mortality rate following treatment with statins]; however, whether the effects of statins on macrophage function will translate to human clinical benefit is uncertain, as the doses used to achieve the in vitro effects were higher than those typically used clinically.
Pulmonary Macrophage-Targeted Therapies-The Way Forward in Chronic Inflammatory Lung Diseases?: Sandra Hodge
Journal of Pulmonary & Respiratory Medicine welcomes articles related to "Pulmonary macrophages"
Last date updated on June, 2014